http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009155284-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d79c71c721f8ad5e60133a7e2383935 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75c8862f1501908d6ac7d0817686127d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate | 2008-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66612657a5f07673fa672933fac4e4b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_411752ac9c5aee12fbe7b2c79d633a23 |
| publicationDate | 2009-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2009155284-A1 |
| titleOfInvention | Hgf-sf monoclonal antibody combinations |
| abstract | The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014108854-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10595950-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102692505-A |
| priorityDate | 1999-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 290.